Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 144, Issue 5, 2006, Pages 337-343

  Sotelo, Julio ^a   Briceño, Eduardo ^a   López González, Miguel Angel ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARMUSTINE; CHLOROQUINE; PLACEBO; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BLOOD EXAMINATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYE EXAMINATION; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SEIZURE; SURVIVAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; MIDDLE AGED; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CHLOROQUINE; DOUBLE-BLIND METHOD; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 33645115547     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-5-200603070-00008     Document Type: Article

References (49)

1. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31:635-44.
2. Kanzawa T, Ito H, Kondo Y, Kondo S. Current and future gene therapy for malignant gliomas. J Biomed Biotechnol. 2003;2003:25-34.
3. Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemure JG, et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004;101:2098-105.
4. Lopez-Gonzalez MA, Sotelo J. Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol. 2000;53:157-62.
5. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853-60.
6. Briceño E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. Accessed at www.aans.org/education/journal/neurosurgical/feb03/14-2-3.pdf on 8 June 2005.
7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3:722-7.
8. Giampietri A, Fioretti MC, Goldin A, Bonmassar E. Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J Natl Cancer Inst. 1980;64:297-301.
9. Bennett A, Melhuish PB, Patel S, Randles H, Stamford IF. Cancer in mice: effects of prednisolone or mepacrine alone and with cytotoxic drugs. Br J Cancer. 1987;55:385-8.
10. Reyes S, Herrera LA, Ostrosky P, Sotelo J. Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery. 2001;49:969-73.
11. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285:1992-5.
12. National Cancer Institute. Common toxicity criteria. Version 2; 1999. Accessed at www.fda.gov/cder/cancer/toxicityframe.htm on 8 June 2005.
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
14. Capala J, Carlsson J. Influence of chloroquine and lidocaine on retention and cytotoxic effects of [131I]EGF: studies on cultured glioma cells. Int J Radiat Biol. 1991;60:497-510.
15. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol. 2000;165:1534-40.
16. Riccio ES, Lee PS, Winegar RA, Krogstad DJ, De D, Mirsalis JC. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ Mol Mutagen. 2001;38:69-79.
17. Itaka K, Yamauchi K, Harada A, Nakamura K, Kawaguchi H, Kataoka K. Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency. Biomaterials. 2003;24:4495-506.
18. Ferrante A, Goh DH. The effect of anti-malarial drugs on human natural killer cells in vitro. Parasite Immunol. 1984;6:571-80.
19. Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med. 1983;75:19-24.
20. Nosál R, Jancinová V. Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)). Thromb Res. 2002;105:339-45.
21. Pozzi D, Zompetta C, Faggioni A, Lisi A, De Ros I, Ravagnan G, et al. Early events of fusion between Epstein Barr virus and human lymphoblastoid cells (Raji) detected by R18 fluorescence dequenching measurements. Membr Biochem. 1990;9:239-51.
22. Kunze H, Hesse B, Bohn E. Effects of antimalarial drugs on several rat-liver lysosomal enzymes involved in phosphatidylethanolamine catabolism. Biochim Biophys Acta. 1982;713:112-7.
23. Pacuszka T, Fishman PH. Metabolism of cholesterol, phosphatidylethanolamine and stearylamine analogues of GM1 ganglioside by rat glioma C6 cells. Biochim Biophys Acta. 1991;1083:153-60.
24. Hostetler KY, Reasor M, Yazaki PJ. Chloroquine-induced phospholipid fatty liver. Measurement of drug and lipid concentrations in rat liver lysosomes. J Biol Chem. 1985;260:215-9.
25. Nielsen FC, Gammeltoft S, Westermark B, Fahrenkrug J. High affinity receptors for vasoactive intestinal peptide on a human glioma cell line. Peptides. 1990;11:1225-31.
26. Law PY, Hom DS, Loh HH. Down-regulation of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. Chloroquine promotes accumulation of tritiated enkephalin in the lysosomes. J Biol Chem. 1984;259:4096-104.
27. Yin F, Guo M, Yao S. Kinetics of DNA binding with chloroquine phosphate using capacitive sensing method. Biosens Bioelectron. 2003;19:297-304.
28. Yeo SJ, Gravis D, Yoon JG, Yi AK. Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. J Biol Chem. 2003;278:22563-73.
29. Zhu FG, Reich CF, Pisetsky DS. Effect of cytofectins on the immune response of murine macrophages to mammalian DNA. Immunology. 2003;109:255-62.
30. Allison JL, O'Brien RL, Hahn FE. DNA: reaction with chloroquine. Science. 1965;149:1111-3.
31. Cohen SN, Yielding KL. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci U S A. 1965;54:521-7.
32. Tchernaenko V, Halvorson HR, Lutter LC. Topological measurement of an A-tract bend angle: variation of duplex winding. J Mol Biol. 2003;326:751-60.
33. Snyder RD, Arnone MR. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat Res. 2002;503:21-35.
34. Snyder RD. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen. 2000;35:13-21.
35. Kaneko T, Mizushima T, Ohtsuka Y, Kurokawa K, Kataoka K, Miki T, et al. Co-induction of DNA relaxation and synthesis of DnaK and GroEL proteins in Escherichia coli by expression of LetD (CcdB) protein, an inhibitor of DNA gyrase encoded by the F factor. Mol Gen Genet. 1996;250:593-600.
36. Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res. 1994;54:2959-63.
37. Teulade-Fichou MP, Hounsou C, Guittat L, Mergny JL, Alberti P, Carrasco C, et al. Molecular recognition of quadruplex DNA by quinacridine derivatives. Nucleosides Nucleotides Nucleic Acids. 2003;22:1483-5.
38. Biller H, Schachtschabel DO, Leising HB, Pfab R, Hess F. [Influence of x-rays and quinacrine (atebrine) or chloroquine (resochine) - alone or in combination - on growth and melanin formation of Harding-Passey melanoma cells in monolayer culture]. Strahlentherapie. 1982;158:450-6.
39. Sohn TA, Bansal R, Su GH, Murphy KM, Kern SE. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002;23:949-57.
40. Pfab R, Schachtschabel DO, Kern HF. [Ultrastructural studies of the effect of x-rays and quinacrine (Atebrin) or chloroquine (Resochin) - alone or in combination - on Harding-Passey melanoma cells in monolayer culture]. Strahlentherapie. 1985;161:711-8.
41. Rudling MJ, Collins VP, Peterson CO. Delivery of aclacinomycin A to human glioma cells in vitro by the low-density lipoprotein pathway. Cancer Res. 1983;43:4600-5.
42. Inaba M, Maruyama E. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine. Cancer Res. 1988;48:2064-7.
43. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun. 1988;153:959-66.
44. Filippov A, Skatova G, Porotikov V, Kobrinsky E, Saxon M. Ca2+-antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. Gen Physiol Biophys. 1989;8:113-8.
45. Cho J, Rando RR. Specific binding of Hoechst 33258 to site 1 thymidylate synthase mRNA. Nucleic Acids Res. 2000;28:2158-63.
46. Dalpke AH, Opper S, Zimmermann S, Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J Immunol. 2001;166:7082-9.
47. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988;33:454-62.
48. Hawtrey A, Joubert D, van Jaarsveld P, Pieterse A, van Zyl J, Ariatti M. Low concentrations of chlorpromazine and related phenothiazines stimulate gene transfer in HeLa cells via receptor-mediated endocytosis. Drug Deliv. 2002;9:47-53.
49. Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol. 1998;30:357-66.